May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ
NHS strikes deal aimed at eliminating HCV in England
NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they may be infected with HCV. The three companies will provide five HCV drugs at an undisclosed "best price" and work with local health services to test potential patients in isolated communities for infection and provide treatment as needed, an approach that NHS hopes could lead to the elimination of HCV.
Manufacturing deals Acacia another setback at FDA
FDA issued a second complete response letter to an NDA for Barhemsys amisulpride from Acacia Pharma Group plc (Euronext:ACPH), citing continued manufacturing deficiencies. Acacia is seeking approval of the low-dose IV formulation of amisulpride to treat and prevent postoperative nausea and vomiting (see "Acacia Provides Update on Plan to Address PONV Complete Response Letter")...